Friday, 16 October 2026European Markets

SMARTCRAFT Stock Was 14.94% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with SMARTCRAFT (SMCRT.OL) rising 14.94% to kr20.00 on Thursday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.06% to kr1,228.37, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

SMARTCRAFT's last close was kr17.40, 27.8% below its 52-week high of kr24.10.

About SMARTCRAFT

SmartCraft ASA provides software solutions to the construction industry in Norway, Sweden, and Finland. The company offers Cordel; Bygglet, a SaaS born in the cloud solution; EL-VIS, a solution for electricians; and Congrid, a cloud-based tool for project management in construction companies. It also provides HomeRun, a digital tool for construction, project communication, document, and procurement management; Kvalitetskontroll, a cloud-based project management solution and quality assurance platform for construction companies; El-verdi, a digital sales tool for electricians; and ELinn, a cloud based solution for electricians to handle project management services. The company was founded in 1987 and is headquartered in Hønefoss, Norway.

Earnings Per Share

As for profitability, SMARTCRAFT has a trailing twelve months EPS of kr0.43.

PE Ratio

SMARTCRAFT has a trailing twelve months price to earnings ratio of 46.51. Meaning, the purchaser of the share is investing kr46.51 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.68%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SMARTCRAFT's EBITDA is 68.2.

More news about SMARTCRAFT (SMCRT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com